Brent Zettl On Canada’s First Health Canada Approved Clinical Trial With Cannabis

Prairie Plant Systems and CanniMed announced yesterday the beginning of recruitment for their CAPRI Trial (Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee). This clinical trial is Canada’s first randomized, double blind, placebo controlled, proof-of-concept, crossover clinical trial of single dose vaporized cannabis in adults with painful osteoarthritis of the knee. The Saskatoon producer will be partnering with researchers at Dalhousie University and McGill University Health Centre to begin the process in the coming weeks of accepting 40 patients over 50 years of age.

Clinical research in cannabinoids is important because it helps physicians and policy makers better understand and quantify exactly how medical marijuana can help patients. Nearly 5 million Canadians suffer from arthritis. The study will use 5 different cannabinoid profiles as well as a placebo, with a Volcano Medic vaporizer, randomized throughout the course of the study. Individuals interested in taking part in...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.